USP30-IN-20 

USP30-IN-20 is an orally active USP30 inhibitor (K_d = 1.61 μM, IC₅₀ = 12.8 μM). USP30-IN-20 induces ferroptosis by promoting ubiquitination-mediated degradation of GPX4. USP30-IN-20 inhibits the proliferation, migration, invasion, and stemness of prostate cancer cells. USP30-IN-20 induces G0/G1 cell cycle arrest and ROS levels in prostate cancer cells. USP30-IN-20 exhibits significant anti-tumor efficacy in PC3 cell subcutaneous xenografts in mice. USP30-IN-20 can be used for the study of advanced prostate cancer^[1].

USP30-IN-20 (Compound 8m) shows potent anti-proliferative activity against PC3, DU145 prostate cancer cells, and CD24^-CD44⁺ prostate cancer stem-like cells, with IC₅₀ values of 4.87 μM, 5.44 μM, and 5.94 μM, respectively^[1].
USP30-IN-20 (2.5-5 μM, 14 days) significantly reduces the number of malignant colonies of PC3 and DU145 cells^[1].
USP30-IN-20 (2.5-5 μM, 24-48 h) induces G0/G1 phase arrest, inhibits the migration and suppresses the invasion capacity of PC3 and DU145 cells^[1].
USP30-IN-20 (2.5-5 μM, 72 h) disrupts tumor sphere formation and significantly reduces the number of spheroids in PC3 and DU145 cells^[1].
USP30-IN-20 (2.5-5 μM, 24 h) significantly upregulates intracellular ROS and lipid ROS levels, increases malondialdehyde (MDA) content and decreases glutathione (GSH) levels in PC3 and DU145 cells^[1].
USP30-IN-20 (5 μM, 24 h) causes mitochondrial shrinkage, disappearance of mitochondrial cristae and membrane structure, and disruption of mitochondrial membrane potential in PC3 cells, without affecting cell apoptosis^[1].
USP30-IN-20 (2.5-5 μM; 24 h) downregulates GPX4 protein expression in a dose-dependent manner in PC3 and DU145 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

USP30-IN-20 (Compound 8m) (25-50 mg/kg, p.o., daily, 18 days) significantly inhibits the proliferation of PC3 prostate cancer xenograft tumors in male athymic nude mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

353.70

C₁₆H₁₅ClO₂Se

ClC(C=CC=C1)=C1[Se]C2=C(C)C3=C(O2)CC(C)CC3=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Xu L, et al. Discovery of a selenium-containing compound as a promising ferroptosis inducer attenuates prostate cancer progression. Eur J Med Chem. 2025 Dec 5;299:118067.  [Content Brief]